Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 25;12(4):778. doi: 10.3390/cancers12040778

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Gemcitabine-resistant gallbladder cancer patient-derived organoids (GBC-PDOs) are sensitive to Verteporfin treatment. (A) Dose-response curves to gemcitabine generated in GBC-PDOs. GBC-PDOs 1 and 2 are resistant to gemcitabine while GBC-PDOs 3 and 4 are sensitive to gemcitabine, n = 3. (B) Dose-response curves to VP generated in gemcitabine-resistant GBC-PDOs (GBC-PDO1 and GBC-PDO2), n = 3. These plots showed the percentage of viable cells measured by CellTiter Glo assay in response to micromolar doses (data expressed as Log10) at 72 h of treatment with each drug. Results are represented as Mean ± SEM. (C) Representative image of YAP1 expression in GBC-PDOs 1, 2, 3 and 4. Scale bar: 50 µm.